Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

Zacks12-02

Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488954102?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a","is_english":true,"pubTime":"2024-12-02 19:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488954102","market":"us","top_or_hot":-1,"title":"Should You Continue to Retain Bio-Techne Stock in Your Portfolio?","media":"Zacks","content":"<div>\n<p>Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/continue-retain-bio-techne-stock-110600525.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Continue to Retain Bio-Techne Stock in Your Portfolio?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Continue to Retain Bio-Techne Stock in Your Portfolio?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 19:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/continue-retain-bio-techne-stock-110600525.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/continue-retain-bio-techne-stock-110600525.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362540622.SGD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/continue-retain-bio-techne-stock-110600525.html","article_id":"2488954102","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488954102","pubTimestamp":1733137560,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the Ella platform after achieving the ISO 13485 certification. Acquisitions have continued to play an important role in Bio-Techne’s efforts to expand its portfolio and enter adjacent markets. However, adverse macroeconomic impacts and intense rivalry raise concerns for its operations.In the past year, shares of this Zacks Rank #3  company have rallied 15.4%, outperforming the industry’s 0.9% growth. The S&P 500 composite grew 32.4% in the same time frame.The renowned life sciences company has a market capitalization of $11.97 billion. TECH’s earnings surpassed estimates in two of the trailing four quarters and missed on two occasions, delivering an average surprise of 1.55%.Expansion Through Strategic Acquisitions: In recent times, the company has made multiple acquisitions that have expanded","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4198":"医疗保健用品","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","PEN":"Penumbra Inc","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","HAE":"美国血液技术","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4504":"桥水持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4548":"巴美列捷福持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","TECH":"Techne Corporation","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","BSX":"波士顿科学","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4121":"生命科学工具和服务","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc"},"translate_title":"您应该继续在投资组合中保留Bio-Techne股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1,"PEN":1,"HAE":1,"BSX":0.9},"content_text":"Bio-Techne TECH is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the Ella platform after achieving the ISO 13485 certification. Acquisitions have continued to play an important role in Bio-Techne’s efforts to expand its portfolio and enter adjacent markets. However, adverse macroeconomic impacts and intense rivalry raise concerns for its operations.\nIn the past year, shares of this Zacks Rank #3 (Hold) company have rallied 15.4%, outperforming the industry’s 0.9% growth. The S&P 500 composite grew 32.4% in the same time frame.\nThe renowned life sciences company has a market capitalization of $11.97 billion. TECH’s earnings surpassed estimates in two of the trailing four quarters and missed on two occasions, delivering an average surprise of 1.55%. \nLet’s delve deeper.\nTailwinds for TECH\nThe Success of Four Growth Verticals: The first growth vertical is the Proteomics Analytical Instrumentation franchise, marketed under the ProteinSimple brand, which offers lab productivity tools for budget-constrained customers. Bio-Techne reported mid-single-digit growth for this vertical in fiscal 2024, and the same momentum continued in the fiscal first quarter, led by the SimplePlex and SimpleWestern franchise called Leo. The second vertical, Cell and Gene Therapy, led by the company’s quality GMP protein products, is also growing well from healthy biotech funding levels and significant customer additions.\nThird on the list is the Diagnostics and Spatial Biology vertical, where the company is witnessing solid growth despite the budget reset by pharma customers. The newly added RNAscope assays on COMET are showing positive responses. Lastly, the Molecular Diagnostics growth vertical continues to perform at a very high level, with nearly 40% growth in the first quarter of fiscal 2025 in the ExoDx prostate test and the Asuragen kit business.\nElla Garners Promising Opportunities: Following the recent ISO 13485 certification, the company has started to successfully pursue clinical diagnostic opportunities on the Ella automated multiplexing immunoassay instrument platform. This has opened up a large potential end market for this highly sensitive, fast and easy-to-use multiplexing immunoassay instrument. In this regard, the partnership with Novomol-Dx should be mentioned. According to Bio-Techne, Ella is quickly becoming the go-to platform for cell and gene therapy customers for viral titer and release testing. Ella is also seeing rapid adoption among CROs looking for high reproducibility paired with high sensitivity in an easy-to-use, fully automated immunoassay platform.\nImage Source: Zacks Investment Research\nExpansion Through Strategic Acquisitions: In recent times, the company has made multiple acquisitions that have expanded the product offerings and geographic footprint of both operating segments. Following the completion of the Lunaphore acquisition in fiscal 2024, TECH’s initiative to scale up Lunaphore’s instrument production capacity is on track to meet the current and future platform demand.\nThe company also completed a 19.9% investment in Wilson Wolf in fiscal year 2023 and currently plans to acquire the remaining ownership in Wilson Wolf by the end of calendar year 2027. While progressing in this line, during the fiscal first quarter, the company announced the launch of its ProPak GMP Cytokines, which are optimized for use in the Wilson WolfG-Rex bioreactor.\nFactors Weighing on TECH\nChoppy Macro Environment: The challenging macroeconomic scenario, specifically in the Asia Pacific and Europe, is driving the higher-than-anticipated rise in raw materials and labor costs. These could also result in broader economic impacts, affecting the company’s business through 2024.\nCompetitive Landscape: Based on the range of products and services Bio-Techne sells, the company encounters a wide variety of competitors, including many large, global companies or divisions of such companies with substantial capabilities and resources and several smaller, niche competitors with specialized product offerings. Consolidation trends in the pharmaceutical, biotechnology and diagnostics industries have also created fewer customer accounts and concentrated purchasing decisions for some customers, resulting in increased pricing pressure on Bio-Techne.\nTECH Stock Estimate Trend\nIn the past 30 days, the Zacks Consensus Estimate for the company’s fiscal 2025 earnings has moved down 6 cents to $1.92.\nThe Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $1.22 billion, suggesting a 5.6% rise from the year-ago reported number.\nTop MedTech Stocks\nSome better-ranked stocks in the broader medical space are Haemonetics HAE, Boston Scientific BSX and Penumbra PEN.\nHaemonetics has an earnings yield of 5.41% compared with the industry’s 1.75%. Haemonetics’ earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed on one occasion, the average surprise being 2.82%. Its shares have risen 8.9% compared with the industry’s 21.2% growth in the past year.\nHAE carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nBoston Scientific, carrying a Zacks Rank #2 at present, has a long-term estimated earnings growth rate of 13.8%. Shares of the company have surged 63.4% compared with the industry’s 23.1% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.29%.\nPenumbra, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 35.3% for 2024 compared with the industry’s 12.8%. Shares of Penumbra have risen 7.8% compared with the industry’s 15.1% growth over the past year. PEN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nBio-Techne Corp (TECH) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488954102"}